ONCAlert | Upfront Therapy for mRCC

Mantle Cell Lymphoma VIEW MORE >>

A Biologics License Application for the investigational chimeric antigen receptor T-cell therapy agent, KTE-X19, was accepted by the FDA and granted Priority Review for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, according to a press release from Kite, developer of KTE-X19. 

Latest JournalAll Journals >>

Evolving Paradigms Mantle Cell Lymphoma
Evolving Paradigms

The Targeted Oncology mantle cell lymphoma resource center serves as a hub for all clinical news and expert insights related to this rare subtype of non-Hodgkin lymphoma. Content found here includes video interviews with lymphoma experts and key opinion leaders in the field sharing their perspectives on existing mantle cell lymphoma treatment options and management approaches, including case studies that describe the clinical presentation and diagnostic criteria for patients with MCL.

This page also houses the most recent issue of Evolving Paradigms: Mantle Cell Lymphoma. This educational journal offers information regarding mantle cell lymphoma prognosis, staging, and risk, as well as current and emerging therapies for the disease.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.